IP Library Granted Patent US 12710434
Granted Patent B2
US 12710434 · App. 18/230,356 · Granted Aug 18, 2026

Red cell diluent with chelating agent and methods for making and using the same

Inventors: Mortimer Alzona (Norcross, GA); Bryan Marshall (Norcross, GA); Elizabeth Cope (Norcross, GA); Margot Borgel (Norcross, GA); Teresa Welch (Norcross, GA)
Assignee: Immucor, Inc.
G01N33/80G01N1/38G01N33/5005G01N33/6854
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12710434
App. No.
18/230,356
Filed
Aug 4, 2023
Granted
Aug 18, 2026
Kind
B2
Art Unit
1678
USPC
435/7.23
Abstract

The present disclosure relates to a RBC solution comprising ethylenediaminetetraacetic acid (EDTA) and methods for making and using the same. The solution can comprise EDTA at a concentration from 3-5 g/L, including 4 g/L. Well plates prepared using the solution can provide a decreased rate of false positive results in automated immunoassays for detecting RBC antibodies in a patient sample.

Claims (27)

1 . A method comprising:

preparing a red blood cell (RBC) solution comprising RBCs and a chelating agent, the RBCs comprising antigens to antibodies to be identified in a patient sample;

applying the RBC solution to a structure to cause the RBCs in the solution to be adhered to a surface of the structure; and

applying a drying solution to the structure having the RBCs or fragments of the RBCs adhered to the surface of the structure.

2 . The method of claim 1 , wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA).

3 . The method of claim 2 , wherein the RBCs comprise packed RBCs.

4 . The method of claim 3 , wherein the EDTA comprises one or more of disodium EDTA and tetrasodium EDTA.

5 . The method of claim 4 , wherein the solution comprises EDTA at a concentration from about 3 g/L (grams per liter) to about 5 g/L.

6 . The method of claim 5 , wherein the concentration of EDTA is about 4 g/L.

7 . The method of claim 1 , further comprising:

applying a lysing agent to RBCs adhered to the structure to produce the fragments of the RBCs.

8 . The method of claim 7 , wherein the RBC fragments comprise at least one of RBC membranes or RBC stroma.

9 . The method of claim 1 , further comprising, prior to applying the RBC solution:

applying attachment molecules to the structure; and

incubating the attachment molecules so that the attachment molecules adhere to the surface of the structure;

wherein the RBCs or the fragments of the RBCs are bound to respective attachment molecules.

10 . The method of claim 9 , further comprising, after the RBCs or the fragments of the RBCs are bound to respective attachment molecules:

washing the structure, thereby leaving the RBCs or the fragments of the RBCs bound to the respective attachment molecules.

11 . The method of claim 1 , further comprising:

following application of the drying solution, curing the structure having the RBCs or the fragments of the RBCs adhered to the surface of the structure for a period of time.

12 . The method of claim 11 , wherein the period of time is at least three days.

13 . The method of claim 1 , wherein the structure comprises a well, a plate, or a strip.

14 . The method of claim 1 , further comprising:

incorporating the structure having the RBCs or the fragments of the RBCs adhered to the surface thereof into a kit.

15 . The method of claim 14 , wherein the kit comprises:

low ionic strength saline (LISS) solution; and

indicator cells coated with anti-IgG antibody.